Aspire Biopharma Statistics
Share Statistics
Aspire Biopharma has 49.53M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 49.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 48,377 |
| FTD / Avg. Volume | 6.83% |
Short Selling Information
The latest short interest is 98.37K, so 0.2% of the outstanding
shares have been sold short.
| Short Interest | 98.37K |
| Short % of Shares Out | 0.2% |
| Short % of Float | 0.28% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -7.57 and the forward
PE ratio is null.
Aspire Biopharma's PEG ratio is
0.
| PE Ratio | -7.57 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -61.61 |
| P/FCF Ratio | -357.83 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aspire Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09,
with a Debt / Equity ratio of -0.82.
| Current Ratio | 0.09 |
| Quick Ratio | 0.09 |
| Debt / Equity | -0.82 |
| Debt / EBITDA | -0.11 |
| Debt / FCF | -4.78 |
| Interest Coverage | -3.46 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-6,268,736 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.91, so Aspire Biopharma's
price volatility has been higher than the market average.
| Beta | 0.91 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 24.64 |
| Average Volume (20 Days) | 707,869 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.09M |
| Net Income | -12.54M |
| EBITDA | -11.65M |
| EBIT | -11.65M |
| Earnings Per Share (EPS) | -1.52 |
Full Income StatementBalance Sheet
The company has 3.63K in cash and 1.27M in
debt, giving a net cash position of -1.26M.
| Cash & Cash Equivalents | 3.63K |
| Total Debt | 1.27M |
| Net Cash | -1.26M |
| Retained Earnings | -2.78M |
| Total Assets | 147.99K |
| Working Capital | -1.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -265.19K
and capital expenditures 0, giving a free cash flow of -265.19K.
| Operating Cash Flow | -265.19K |
| Capital Expenditures | n/a |
| Free Cash Flow | -265.19K |
| FCF Per Share | -0.03 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
